New research builds on evidence that diet, certain brain training exercises and physical activity can delay the decline of ...

A new result shows that just about anyone at risk for Alzheimer’s – and that’s most of us – can change the trajectory of ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...

K-Bio showcases AI and protein removal advancements for dementia at Toronto conference Innovations in dementia treatment ...

ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. As a new generation of ...

Shigeta Animal Pharmaceuticals, established in 1984 in Toyama Prefecture, was notable for developing the first canine/feline ...

A ground-breaking study gives those with elevated Alzheimer’s risk a new path for changing the trajectory of their brain health. The researchers reported a significant improvement in global cognition ...

South Korean pharmaceutical and biotech companies are presenting their latest Alzheimer’s research at the world’s largest ...

People who walk 7,000 steps a day have a dramatically lower risk of a broad range of serious health problems, the largest review of the evidence yet said. The most widely promoted target for people ...

Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer's associated amyloid pa ...